1841078-75-8Relevant articles and documents
Discovery of 6-(Fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)
Walji, Abbas M.,Hostetler, Eric D.,Selnick, Harold,Zeng, Zhizhen,Miller, Patricia,Bennacef, Idriss,Salinas, Cristian,Connolly, Brett,Gantert, Liza,Holahan, Marie,O'Malley, Stacey,Purcell, Mona,Riffel, Kerry,Li, Jing,Balsells, Jaume,Obrien, Julie A.,Melquist, Stacey,Soriano, Aileen,Zhang, Xiaoping,Ogawa, Aimie,Xu, Serena,Joshi, Elizabeth,Della Rocca, Joseph,Hess, Fred J.,Schachter, Joel,Hesk, David,Schenk, David,Struyk, Arie,Babaoglu, Kerim,Lohith, Talakad G.,Wang, Yaode,Yang, Kun,Fu, Jianmin,Evelhoch, Jeffrey L.,Coleman, Paul J.
, p. 4778 - 4789 (2016/06/13)
Neurofibrillary tangles (NFTs) made up of aggregated tau protein have been identified as the pathologic hallmark of several neurodegenerative diseases including Alzheimer's disease. In vivo detection of NFTs using PET imaging represents a unique opportuni
PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES
-
Page/Page column 46, (2016/01/01)
Pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts are disclosed, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha- synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, the compounds are used as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. Futher, the compounds are useful for measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.